Turn Therapeutics (NASDAQ:TTRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Several other equities analysts have also recently issued reports on TTRX. Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th. WBB Securities upgraded shares of Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 price objective for the company in a research report on Friday, October 23rd. Weiss Ratings cut shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. LADENBURG THALM/SH SH raised shares of Turn Therapeutics to a “strong-buy” rating in a report on Monday, July 20th. Finally, Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Turn Therapeutics Stock Performance

NASDAQ:TTRX opened at $9.65 on Friday. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The stock’s 50 day simple moving average is $11.73 and its 200-day simple moving average is $7.04. Turn Therapeutics has a 12-month low of $2.57 and a 12-month high of $16.45.

Turn Therapeutics (NASDAQ:TTRX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. As a group, analysts expect that Turn Therapeutics will post -0.40 earnings per share for the current year.

Institutional Trading of Turn Therapeutics

Several hedge funds have recently modified their holdings of the business. Ieq Capital LLC acquired a new position in Turn Therapeutics during the second quarter worth $1,660,000. BlackRock Inc. purchased a new position in Turn Therapeutics in the second quarter worth $282,000. Bridgewater Advisors Inc. purchased a new position in Turn Therapeutics in the second quarter worth $242,000. Jefferies Financial Group Inc. purchased a new position in Turn Therapeutics in the second quarter worth $119,000. Finally, Bank of America Corp DE acquired a new stake in Turn Therapeutics in the second quarter valued at $103,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.